Information Provided By: 
Fly News Breaks for March 20, 2019
LLY
Mar 20, 2019 | 06:35 EDT
UBS analyst Navin Jacob resumed coverage of Eli Lilly with a Buy rating, also raising his price target to $140 from $131. The analyst says the consensus on the stock does not fully value the "strength & growth" of the company's Human Health business, which he expects to become more apparent following the Elanco (ELAN) spinoff. Jacob adds that Eli Lilly should be able to achieve its 2020 operating margin guidance of over 31% amid impressive Trulicity growth and strong volumes for Jardiance.
News For LLY From the Last 2 Days
There are no results for your query LLY
